Home Sports Prescient Therapeutics (ASX:PTX) Unveils New CAR-T Treatment – The Market Herald

Prescient Therapeutics (ASX:PTX) Unveils New CAR-T Treatment – The Market Herald

25
0

Sign up

Be the first with news that moves the market

  • Prescient Therapeutics (PTX) introduces a new adjuvant to enhance cellular immunotherapy
  • CellPryme-A was designed to be given to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as the CAR-T cell therapy PTX.
  • Prescient Presents Data for CellPryme-A at Seventh Annual CAR-TCR Summit in Boston
  • The company says CellPryme-A is now ready for clinical trials and can be incorporated into clinical trials of existing cell therapies
  • Prescient Therapeutics fell 1.35 percent to trade at 18 cents at 1:29 p.m. AEST.

Prescient Therapeutics (PTX) has introduced a new adjuvant to enhance cellular immunotherapy.

The CellPryme-A product was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as the CAR-T cell therapy PTX. This is used to combat the hostile tumor microenvironment faced by cellular immunotherapy.

CellPryme-A can be administered before or together with cellular immunotherapy.

CellPryme-A has been shown in animal models to reduce the number of suppressive regulatory T cells that surround solid tumors, reducing the effectiveness of CAR-T and other cancer treatments, Prescient said.

While CellPrymeA demonstrated superior tumor destruction and host survival in preclinical studies, its effect was even greater when used in conjunction with Prescient’s CellPryme-M CAR-T manufacturing technology.

The company presented this new data at the seventh annual CAR-TCR Summit in Boston.

Prescient President and CEO Stephen Yatomi-Clark said the company was pleased to “finally” introduce CellPryme-A as a separate but complementary addition to CellPryme-M.

“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient occupies an enviable position at the forefront of cellular immunotherapy, creating technologies that overcome the challenges facing the field,” said Mr Yatomi-Clark.

The company said CellPryme-Awas is now ready for clinical trials and can be incorporated into clinical trials of existing cellular therapies.

Prescient Therapeutics fell 1.35 percent to trade at 18 cents at 1:29 p.m. ET.

https://themarketherald.com.au/prescient-therapeutics-asxptx-unveils-new-treatment-to-boost-car-t-performance-2022-09-23/

Previous articleThe trial of Brittany Higgins’ alleged rapist will exclude jurors who follow her on Twitter
Next articleWallabies must turn hard luck into heroics to make Bledisloe history at Eden Park | Australian national rugby union team